Continuous subcutaneous apomorphine infusion does not impair the dynamics of cognitive action control in mild to moderate Parkinson’s disease
Journal of Neurology, Neurosurgery & Psychiatry
Fecha de publicación: Marzo 2018
Autores: Joan Duprez, JeanFrançois Houvenaghel, Sophie Drapier, Manon Auffret, Dominique Drapier, Gabriel Robert, Marc Vérin, Paul Sauleau
Background: Continuous subcutaneous apomorphine infusion (CSAI) is increasingly used in Parkinson’s disease (PD), notably in patients contraindicated for subthalamic deep brain stimulation. Although it has been suggested that CSAI is safe regarding cognition, few studies have actually investigated its effect, especially on cognitive control which is a crucial process for goal-directed behavior.